Literature DB >> 6469399

Vinblastine and vincristine--growth-inhibitory effects correlate with their retention by cultured Nb 2 node lymphoma cells.

P W Gout, R L Noble, N Bruchovsky, C T Beer.   

Abstract

Vinblastine (VLB) and vincristine (VCR) have been compared with respect to their inhibitory effects on the growth of cultured Nb2 node rat lymphoma cells and their binding and release by these cells. When examined over a wide concentration range, the two alkaloids were found to be almost equally effective in inhibiting culture growth, providing they were continuously present in the incubation medium. A striking difference was found, however, when the cells were incubated for short periods with the alkaloids and then restored to alkaloid-free medium for further incubation. Cells treated with VCR (5 X 10(-9) g/ml) for 3 h and washed free of extracellular alkaloid failed to resume normal proliferation during a subsequent 48 h incubation period in alkaloid-free medium. In contrast, cells treated with VLB at a higher concentration (5 X 10(-8) g/ml) and for a longer time (7 h), rapidly resumed growth in alkaloid-free medium. Binding studies, using (3H)VLB and (3H)VCR, showed that when cells were incubated continuously with the alkaloids at a given concentration, they bound equal amounts of the drugs. When labelled cells were resuspended in alkaloid-free medium, VLB was released very readily by the cells, whereas VCR was tenaciously retained. The findings indicate that the growth-inhibitory effects of VLB and VCR are related to the amount of alkaloid associated with the cells and that the long-lasting effects of VCR, relative to VLB, are very likely due to the retention of VCR by the cells when the extracellular alkaloid levels decline. The study also suggests that, in the treatment of malignancies, VLB could be more effective if its extracellular levels were maintained, e.g. by continuous administration.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6469399     DOI: 10.1002/ijc.2910340216

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  5 in total

1.  Antiproliferative activity of vinorelbine (Navelbine) against six human melanoma cell lines.

Authors:  A Photiou; M N Sheikh; D Bafaloukos; S Retsas
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

2.  Comparative uptake, retention and action of vincristine, vinblastine and vindesine on murine leukaemic lymphoblasts sensitive and resistant to vincristine.

Authors:  M P Rivera-Fillat; J Pallarés-Trujillo; C Domènech; M R Grau-Oliete
Journal:  Br J Pharmacol       Date:  1988-04       Impact factor: 8.739

3.  Relationship between the cellular accumulation and the cytotoxicity of S12363, a new Vinca alkaloid derivative.

Authors:  A Pierré; V Pérez; S Léonce; J A Boutin; D Saint-Dizier; P Hautefaye; G Lavielle; G Atassi
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  Effects of the ACTH(4-9) analogue, ORG 2766, on vincristine cytotoxicity in two human lymphoma cell lines, U937 and U715.

Authors:  B Kiburg; A A van de Loosdrecht; K M Schweitzer; G J Ossenkoppele; L J Müller; J J Heimans; P C Huijgens
Journal:  Br J Cancer       Date:  1994-03       Impact factor: 7.640

5.  Vinflunine in the treatment of bladder cancer.

Authors:  Mark Bachner; Maria De Santis
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.